Document:

EX-10.12

 Exhibit 10.12 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is not material and
would likely cause competitive harm to the registrant if publicly disclosed. 
 - translation - 

License and research agreement 

between 
 Het Nederlands Kanker
Instituut 
 and 

Agendia B.V. 

							
	 Index:
	 		  			
			
	 Article 1
	 	 Definitions and interpretation
	  	 	3	 
	 Article 2
	 	 License and options
	  	 	6	 
	 Article 3
	 	 Access to Tumor Series
	  	 	8	 
	 Article 4
	 	 Subcontracting testing work regarding gene expression profiling
	  	 	9	 
	 Article 5
	 	 Payments
	  	 	10	 
	 Article 6
	 	 No warranties
	  	 	10	 
	 Article 7
	 	 License to NKI
	  	 	11	 
	 Article 8
	 	 Grant, maintenance and invalidity
	  	 	11	 
	 Article 9
	 	 Infringement
	  	 	12	 
	 Article 10
	 	 Duration and termination
	  	 	12	 
	 Article 11
	 	 Consequences of termination
	  	 	12	 
	 Article 12
	 	 Secrecy and disclosure
	  	 	13	 
	 Article 13
	 	 Notices
	  	 	14	 
	 Article 14
	 	 Nontransferable
	  	 	15	 
	 Article 15
	 	 Other provisions
	  	 	15	 
	 Article 16
	 	 Applicable law and competent court
	  	 	15	 

  
 2 

 LICENSE AND RESEARCH AGREEMENT 

THE UNDERSIGNED: 
  

	1.	 HET NEDERLANDS KANKER INSTITUUT, an association with full legal competence, having its registered office
in Amsterdam and having a principal place of business in Amsterdam, at the address (1066 CX) Plesmanlaan 121 (“NKI”), in this matter legally represented by the chairman of its Board of Directors, [***] 

and 
  

	2.	 AGENDIA B.V., a private company with limited liability, having its registered office in Amsterdam
and having a principal place of business in Amsterdam, at the address (1066 CX) Plesmanlaan 121 (“Agendia”), [***]; 

NKI and Agendia hereinafter collectively referred to as: the “Parties” and each individually as: a “Party” 

WHEREAS: 
  

	A.	 NKI has the goal of controlling cancer by means of patient care, research and education. Within the framework
of its collaboration [***], NKI has obtained, either as owner, or as licensee, certain rights regarding technology; 

 PARTIES HEREBY
AGREE AS FOLLOWS: 
  

	Article 1	 Definitions and interpretation 

 

	1.1	 In this Agreement the following terms shall have the following meanings, which are identifiable by the use of a
capital: 

  

			
	“Agendia”	  	the private company with limited liability Agendia B.V., registered in the trade register of the Chamber of Commerce and Industry for Amsterdam under number 34185452;

  
 3 

			
	“Agreement”	  	this license agreement as well as all Annexes thereto;
		
	Annex(es)	  	an annex to this Agreement, forming an inseparable and integral constituent thereof;
		
	“Article”	  	an article in this Agreement;
		
	“Collaboration Agreements”	  	[***]
		
	“DNA Microarray Profiling”	  	determining gene activity utilizing DNA microarray technology;
		
	“Effective Date”	  	the effective date of this Agreement, i.e., July 10, 2003;
		
	“Founder’s Lab”	  	the current laboratory, used by, among others, Prof. Dr. R. Bernards and Dr. L.J. van’t Veer, though only to the extent of the microarray profiling part;
		
	“Area”	  	the whole world;
		
	“Use”	  	use for DNA Microarray Profiling;
		
	“Rights of Use”	  	the rights that NKI has obtained or will obtain under the Collaboration Agreements to use of Patents and rights of intellectual property in the field of DNA Microarray Profiling;
		
	“Gene Expression Profiling”	  	determining the activity of genes in biological material
		
	“Joint Research Committee”	  	the joint research committee, consisting of a chairman appointed by NKI, two members appointed by NKI and two members appointed by Agendia.
		
	“NKI”	  	the association with full legal competence Het Nederlands Kanker Instituut, registered in the trade register of the Chamber of Commerce and Industry for Amsterdam under number
40530817;

  
 4 

			
	“NKI Patents”	  	the Patents that NKI has obtained or will obtain as owner under the Collaboration Agreements in the field of DNA Microarray Profiling;
		
	“NKI IP Rights”	  	all rights of intellectual property and all NKI Patents that NKI has obtained or will obtain under the Collaboration Agreements in the field of DNA Microarray Profiling;
		
	“Parties”	  	Agendia and NKI collectively;
		
	“Patents”	  	patents, patent applications and titles to patent and the know-how related thereto, as well as:
		
		  	 (i) all patent applications that are filed in the Area and which lawfully claim priority of
one of the patents and patent applications referred to above;
  

	  	 (ii)  the patents that are awarded on the basis of all applications referred
to;

		
	“Patient Related DNA Profiling”	  	determining the activity of genes in biological material;
		
	“Tumor Series”	  	the tumor series known to Parties from NKI’s frozen tumor bank, though exclusively to the extent these tumor series relate to microarray profiling;
		
	“Confidential Information”	  	all information and data that either Party receives from the other Party and that is indicated as confidential, or whose confidential nature the receiving Party knows or must reasonably be deemed to know, including research
information, technical, financial and business information, the know-how related to Patents, the Tumor Series and related information, data regarding actual or potential customers or partners or intended
business transactions, reports, plans, computer program, computer files, drawings, models, knowhow, show-how, as well as all other information that must reasonably be deemed to be confidential and all papers
and datafiles in which that information is contained.

  
 5 

			
		  	The term “Confidential Information”, however, shall not comprise information that:
		
		  	 (i)  is already known to the public or is becoming known to the public, other than
by a violation by the receiving Party of one or more of its obligations under this Agreement;

		
		  	 (ii)  was already in the possession of the receiving Party before it received that
information from the other Party, to the extent it can demonstrate this on the basis of written records;

		
		  	 (iii)   is the same as information that is received by the receiving Party
from a third party, not bound by any duty of secrecy regarding that information;

  

	1.2	 In the definitions as contained in this Article 1 the singular shall be deemed to comprise the plural
and vice versa. 

  

	Article 2	 License and Options 

 

	2.1	 NKI hereby grants to Agendia, and Agendia hereby accepts from NKI, the exclusive, nontransferable and
royalty-free right to use the NKI IP rights and the Rights of Use exclusively for the Use in the Area for the duration of this Agreement and under the conditions and provisions as set forth in this Agreement. 

 

	2.2	 NKI hereby grants to Agendia, and Agendia hereby accepts from NKI, an exclusive option to obtain an exclusive,
nontransferable and royalty-free license under all Patents that NKI obtains within two years of the date of signature of this Agreement with respect to the results arising from the research that NKI conducts in the Founders Lab in the field of Gene
Expression Profiling. This license is subject to the provisions of this Agreement. 

  
 6 

 If and to the extent Agendia has not exercised the aforementioned option before
December 1, 2005 and NKI in respect of the Patents mentioned desires to grant a license to third parties, the license rights to be granted shall first be offered to Agendia. If and to the extent Parties thereafter are unable within 30 (thirty)
days of such offer to reach agreement on the license terms involved, NKI is free to offer the license rights to one or more third parties (“Third Party”), provided that the license terms in any case are not more favorable than offered
earlier by Agendia to NKI. NKI shall communicate the definitive offer of the Third Party to Agendia after which Agendia has 14 (fourteen) days’ time to make an identical and irrevocable offer to NKI. If Agendia makes such an offer, NKI shall
reject the offer of the Third Party and accept the offer of Agendia. 
  

	2.3	 NKI hereby grants to Agendia, and Agendia hereby accepts from NKI, an exclusive option to obtain an exclusive,
nontransferable and royalty-free license under all Patents that NKI obtains within two years of the date of signature of this Agreement in the field of Patient Related DNA Profiling. This license is subject to the provisions of this Agreement.

 If and to the extent Agendia has not exercised the aforementioned option before December 1, 2005 and NKI in respect
of the Patents mentioned desires to grant a license to third parties, the license rights to be granted shall first be offered to Agendia. If and to the extent Parties thereafter are unable within 30 (thirty) days of such offer to reach agreement on
the license terms involved, NKI is free to offer the license rights to one or more third parties (“Third Party”), provided that the license terms in any case are not more favorable than offered earlier by Agendia to NKI. NKI shall
communicate the definitive offer of the Third Party to Agendia after which Agendia has 14 (fourteen) days’ time to make an identical and irrevocable offer to NKI. If Agendia makes such an offer, NKI shall reject the offer of the Third Party and
accept the offer of Agendia. 
  

	2.4	 Agendia is entitled in respect of the NKI IP Rights and Rights of Use to provide nontransferable and non-sublicensable sublicenses, though exclusively so on business and market terms. 

  

	2.5	 Agendia shall make an effort to the best of its ability to (i) make the exploitation of the NKI IP Rights
and Rights of Use a commercial success and (ii) realize the profits to be made regarding that exploitation in Agendia. 

  

	2.6	 Agendia is aware and accepts that NKI under the Collaboration Agreements has obtained non-exclusive Rights of Use from parties to those Collaboration Agreements. [***] 

  
 7 

	2.7	 Agendia is aware and accepts that the terms that apply to the Rights of Use granted to NKI under the
Collaboration Agreements [***]. 

  

	2.8	 NKI is and shall remain entitled at all times itself to use the IP Rights and Rights of Use licensed to Agendia
under this Agreement, with the proviso that those IP Rights and Rights of Use can only be used for research purposes of NKI and expressly not for any commercial use. 

 

	2.9	 [***] 

  

	Article 3	 Access to Tumor Series 

 

	3.1	 Agendia has the right to propose Tumor Series that it desires to have access to. Such proposal is decided upon
by the Joint Research Committee. These decisions will be made at all times by the Joint Research Committee by a simple majority of votes. In case of a tie of votes, the vote of the chairman of the Joint Research Committee is decisive.

  

	3.2	 The Tumor Series and the tissue samples belonging thereto are and remain at all times the exclusive property of
NKI. NKI is entitled to refuse the access to, and the use of, such tissue samples if: 

  

	 	a)	 NKI is liable to do so by law or regulation or at the request of a competent authority, or

  

	 	b)	 one or more patients, or other parties, demand such from NKI. 

 

	3.3	 NKI shall make an effort in order that the activities mentioned in this Article 3, including the collection of
tissue samples from the Tumor Series and the grant of access to, and use of, that collection, comply with the applicable laws and regulations involved. In this regard, however, NKI gives no warranty whatever. 

 

	3.4	 In respect of the tissue samples from the Tumor Series it has obtained access to, Agendia shall take care at
its own expense of the gene expression profiling and standard bioinformatical analysis. 

  
 8 

	3.5	 In respect of the tissue samples from the Tumor Series Agendia has obtained access to, NKI shall take care at
the expense of Agendia of the tumor RNAs, histopathological information and clinical annotation. These activities and the other work of NKI with respect to making the Tumor Series available to Agendia shall be compensated by Agendia to NKI on a cost
price basis. 

  

	3.6	 NKI and Agendia shall be equally entitled to the results of Agendia’s use of the Tumor Series and further
research in that regard, including Patents obtained in respect of these results, with the proviso that NKI shall only be entitled to use those results and Patents for internal research purposes and that the commercial exploitation of these outcomes
and results shall be taken care of by Agendia. All information that NKI receives from Agendia regarding those results shall be regarded as Confidential Information by NKI. Agendia shall at all times grant NKI access to, and inspection of, the
results of Agendia’s use of the Tumor Series. 

  

	3.7	 Agendia indemnifies NKI against all claims of third parties connected with the use of the Tumor Series by
Agendia, or further research activities and/or development activities of Agendia in that regard, to the extent such use is not connected with the purposes set forth in the proposal of Agendia to the Joint Research Committee as referred to in Article
3.1. 

  

	Article 4	 Subcontracting testing work regarding gene expression profiling 

 

	4.1	 NKI shall subcontract testing work regarding Gene Expression Profiling to Agendia. This testing work will be
subcontracted to Agendia on an exclusive basis, if and to the extent the testing work involves NKI’s own clinical patients. 

  

	4.2	 Agendia shall as far as possible give priority to performing said testing work over its other activities, to
the extent similar testing work for other hospitals is not thereby subordinated. If Agendia cannot offer this testing work to NKI, Agendia shall enable NKI (including third-party commissionees of NKI) free of charge to perform this testing work or
have it performed. 

  

	4.3	 Agendia shall perform the testing work subcontracted to it in accordance with a Customer Service Agreement to
be agreed upon between parties. As long as such a Customer Service Agreement has not been agreed upon, Agendia shall perform the testing work in conformity with the reasonable instructions of NKI. 

 

	4.4.	 Agendia shall charge the following costs to NKI for this testing work: 

 

	 	a)	 for NKI’s own clinical patients: [***] 

  
 9 

	 	b)	 for other clinical patients [***] 

 

	 	c)	 for administrative costs that are directly connected with the testing work: [***] 

 

	 	d)	 for NKI-requested research-type bioinformatic services: [***]

  

	 	e)	 for additional necessary QC tests: [***] 

 

	 	f)	 for tests regarding the measuring of tissue samples of patients: [***] 

The cost price in the year 2004 of a test is calculated on the basis of the following formula and is fixed at the following amount: 

[***] 
  

	4.5	 The compensation to be charged to NKI by Agendia shall be increased by VAT. 

 

	Article 5	 Payments 

  

	5.1	 Within 30 (thirty) days after each quarter, Agendia shall submit to NKI an itemized written overview and
associated invoice regarding the testing work performed in that quarter by Agendia for NKI under Article 4 and the compensation due therefor. The compensation shall be paid by NKI to Agendia within 30 (thirty) days after approval of the invoice.

  

	5.2	 Within 30 (thirty) days after each quarter, NKI shall submit to Agendia an itemized written overview and
associated invoice regarding the work performed in that quarter by NKI for Agendia under Article 3 and the compensation due therefor. The compensation shall be paid by Agendia to NKI within 30 (thirty) days after approval of the invoice.

  

	Article 6	 No warranties 

 

	6.1	 NKI does not give any warranties regarding the NKI Patents and Rights of Use. NKI expressly does not warrant:

  
 10 

	 	(i)	 that the NKI Patents and Rights of Use meet the expectations and requirements of Agendia;

  

	 	(ii)	 that the NKI Patents and Rights of Use are suitable for the Use (fitness for purpose);

  

	 	(iii)	 that the use of the NKI Patents and Rights of Use does not infringe any intellectual property right of a third
party; 

  

	6.2	 Agendia indemnifies NKI at all times against all titles, demands and/or claims of third parties and employees
of Agendia in connection with the exploitation and the use of the NKI Patents and Rights of Use by Agendia and/or its sublicensees. 

  

	Article 7	 License to NKI 

 

	7.1	 Except as and to the extent expressly otherwise stipulated in this Agreement, if and to the extent any
intellectual property rights, including Patents, result from the activities of Agendia under this Agreement or the further development of the NKI IP Rights and Rights of Use, Agendia shall inform NKI and keep NKI informed of this in writing at all
times and shall without delay provide to NKI in respect of these intellectual property rights a non-exclusive, worldwide, nontransferable and royalty-free license for use. This license can be used by NKI only
for internal research purposes of NKI and expressly not for commercial purposes. 

  

	7.2	 The license referred to in Article 7.1 comprises the right of NKI to be the first to use the products of
Agendia for clinical-scientific research. 

  

	7.3	 NKI is entitled to have the license(s) referred to in Article 7.1 recorded, at its expense, in the registers
intended therefor. To this end, Agendia shall without delay lend all cooperation and perform all acts necessary. 

  

	Article 8	 Grant, maintenance and invalidity 

 

	8.1	 NKI shall in a timely manner pay all costs of grant and maintenance and perform all necessary acts, or have
them performed, that are needed to get the NKI Patents granted, or to maintain them up to 2 (in words: two) months after the date on which Agendia informs NKI in writing that Agendia desires to forgo (further) maintenance and the use of the NKI
Patents. 

  

	8.2	 NKI shall take care at all times that the NKI Patents remain in the name of NKI, unless Agendia gives written
consent for a different name registration. 

  
 11 

	8.3	 If and to the extent the NKI Patents are not granted, are annulled or otherwise declared to be invalid by any
official body, Agendia cannot derive any claims vis-à-vis NKI from this. 

 

	Article 9	 Infringement 

[***] 
  

	Article 10	 Duration and termination 

 

	10.1	 This Agreement commences on the Effective Date. This Agreement is entered into for an indefinite period of
time. 

  

	10.2	 Parties waive the right to claim dissolution or annulment of this Agreement. 

 

	10.3	 NKI can cancel this Agreement, in whole or in part, with immediate effect by a written notice to Agendia to
that end, if: 

  

	 	(i)	 Agendia is adjudicated bankrupt, [***] 

 

	 	(ii)	 Agendia ceases its enterprise [***] 

 

	 	(iii)	 Agendia acts contrary to one or more of its material obligations under this Agreement [***]

  

	Article 11	 Consequences of termination 

 

	11.1	 If this Agreement ends pursuant to the provisions of Article 10.3, this does not prejudice the rights of either
Party vis-à-vis the other Party that have arisen prior to that, with the proviso that the license rights and option rights granted to Agendia under this Agreement
are canceled immediately. 

  

	11.2	 If and as soon as this Agreement ends, on whatever ground, Agendia shall no longer use or exploit the NKI IP
Rights and Rights of Use and NKI shall no longer exercise the rights licensed to it by Agendia. 

  
 12 

	11.3	 If and as soon as this Agreement ends, on whatever ground, Parties shall immediately, at their own expense:

  

	 	(i)	 either return or destroy all Confidential Information carriers in their possession made available to them by or
on behalf of a Party in connection with this Agreement, as well as all copies thereof, this at the option of the Party on whose behalf that Confidential Information was furnished; 

 

	 	(ii)	 remove all Confidential Information as referred to in Article 12 stored in their computer system and/or files,
therefrom. 

 The provisions in this Article 11.3 do not relate to Confidential Information that NKI must reasonably retain
for the purpose of clinical-scientific research and patient care. 
  

	11.4	 If this Agreement ends, on whatever ground, Parties shall not be liable vis-à-vis each other to any compensation on that ground. 

  

	11.5	 If this Agreement ends, on whatever ground, this does not affect the provisions in the Articles that by their
nature must be deemed to continue after the end of this Agreement, among which, inter alia, Article 14 (Secrecy). 

  

	Article 12	 Secrecy and disclosure 

 

	12.1	 Either Party - including its directors, employees and third parties retained by it - shall observe strict
confidentiality regarding Confidential Information both during, and after the termination of, this Agreement and shall: 

  

	 	(i)	 not disclose Confidential Information to others than those of its employees who should reasonably have that
information at their disposal in connection with the execution of the performances agreed upon; 

  

	 	(ii)	 handle Confidential Information with the same degree of care as observed by either party in respect of its own
data of comparable importance that should remain confidential; 

  

	 	(iii)	 make an effort to store all documents and materials that form or contain Confidential Information in a safe
place and to restrict access thereto to employees who should reasonably have access thereto in connection with the performance of this Agreement; 

  

	 	(iv)	 use Confidential Information exclusively for the purposes for which such has been disclosed to it.

  

	12.2	 The secrecy provisions in Article 12.1 shall not apply if and to the extent: 

 

	 	(i)	 the Party that has disclosed the Confidential Information permits the receiving Party in writing to disclose
that Confidential Information to a third party or third parties, with the proviso that the receiving Party in that case shall impose the obligations arising from Article 12.1 on, and shall have them signed in writing by, that third party or those
third parties; or 

  
 13 

	 	(ii)	 a legal obligation rests with the Party that has received the Confidential Information to disclose the
Confidential Information to the competent authorities; 

  

	 	(iii)	 the disclosure of Confidential Information takes place in the context of the publication by NKI of results of
research it has conducted and in respect of that publication the provisions of Article 12.3 have been complied with by NKI. 

  

	12.3	 At least [***] before the intended publication date, NKI shall submit to Agendia any written, electronic or
oral publication, as well as any document, manuscript or summary, in which information is furnished about matters that are the subject of the intellectual property rights that are licensed to Agendia under this Agreement, as well as the intellectual
property rights as referred to in Article 3.6. If Agendia desires postponement of the publication concerned in order to be able to draft a patent application, it will notify NKI thereof in writing within [***] after submission has taken place. NKI
shall comply with a request for postponement for a maximum of 60 days after the originally intended publication date. 

  

	Article 13	 Notices 

Any notice in connection with this Agreement shall be given by handing over or by transmitting by regular or registered mail, facsimile or e-mail, a written document to that effect to the other Party at the following address: 
  

					
	(i)	 	if the notice is addressed to NKI:
		 	address:	 	[***]
		 		 	
		
		 	fax number:
		
		 	to the attention of [***]
		
	(ii)	 	if the notice is addressed to Agendia:
		 	address:	 	[***]
		 		 	
		 		 	
			
		 	fax number:	 	[***]
		
		 	to the attention of [***]

  
 14 

 or at a different address, if this has been communicated by the receiving Party to the sending Party in
accordance with the provisions in this article. 
  

	Article 14	 Nontransferable 

Parties are not competent to transfer the rights and/or obligations under this Agreement in whole or in part to a third party, to encumber them, to pledge
them, or to grant any limited rights to a third party regarding the subject matter of this Agreement. 
  

	Article 15	 Other provisions 

 

	15.1	 If any provision or part of this Agreement or associated arrangements and agreements should prove invalid or
unenforceable, the other provisions of this Agreement shall remain in full force. Parties shall make an effort to replace the invalid or unenforceable provision(s) by a provision they would have chosen if they had foreseen the invalidity or
unenforceability, which, though, is as much as possible in line with the object of this Agreement. 

  

	15.2	 If a situation arises that this Agreement does not provide for, or if a dispute or difference of opinion should
arise between Parties about a subject that this Agreement does not provide for, they shall make an effort to make an arrangement in mutual consultation that fits in with the line of this Agreement as much as possible. 

 

	15.3	 Any supplementation and/or amendment of this Agreement shall be binding on Parties if this supplementation
and/or amendment has been drawn up in writing and is signed by both Parties. 

  

	Article 16	 Applicable law and competent court 

 

	16.1	 This Agreement is governed exclusively by Dutch law. 

 

	16.2	 All disputes arising from this Agreement, or from further agreements resulting therefrom, shall only be
submitted to the competent court in Amsterdam. 

  
 15 

 THUS AGREED and prepared in duplicate: 

 

									
	1.	 	Het Nederlands Kanker Instituut	 		 	2.	 	Agendia B.V.
					
		 	/s/ A.J.M. Berns	 		 		 	/s/ Dr. S.M. Sixt
					
		 	by: A.J.M. BERNS 	 		 		 	by: Dr. Sixt Holding B.V.
		 	title: Chairman Board of Directors	 		 		 	title: general manager
		 	date: 9-3-2004 	 		 		 	on its behalf:
		 		 		 		 	Dr. B.M. Sixt
		 	at: AMSTERDAM 	 		 		 	 title: managing director under the articles of association

date:
 at: Amsterdam

  
 16EX-10.13

 Exhibit 10.13 

CONVERTIBLE NOTE PURCHASE AGREEMENT 

THIS NOTE PURCHASE AGREEMENT IS SUBJECT TO A SUBORDINATION AND INTERCREDITOR AGREEMENT, DATED AS OF JUNE 8, 2021 (THE “SUBORDINATION
AGREEMENT”), AMONG (I) AGENDIA N.V., (II) AGENDIA, INC., (III) ATHYRIUM OPPORTUNITIES III ACQUISITION LP, AND (IV) EACH OF THE CONVERTIBLE NOTE PURCHASERS PARTY THERETO. THIS NOTE PURCHASE AGREEMENT IS
SUBORDINATED IN RIGHT AND TIME OF PAYMENT TO THE PRIOR PAYMENT IN FULL IN CASH OF ALL OBLIGATIONS (AS DEFINED THEREIN) IN ACCORDANCE WITH, AND TO THE EXTENT SPECIFIED IN, SUCH SUBORDINATION AGREEMENT AND EACH HOLDER OF THIS NOTE PURCHASE AGREEMENT,
BY ITS ACCEPTANCE HEREOF, IRREVOCABLY AGREES TO BE BOUND BY THE TERMS AND PROVISIONS OF SUCH SUBORDINATION AGREEMENT. THIS NOTE PURCHASE AGREEMENT IS ALSO SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN THE SUBORDINATION AGREEMENT. 

CONVERTIBLE NOTE PURCHASE AGREEMENT 

This Note Purchase Agreement, dated as of June 8, 2021 (this “Agreement”), is entered into by and among Agendia
N.V., a public limited company (naamloze vennootschap) incorporated under Dutch law (the “Company”), and the entities listed on the schedule of purchasers attached hereto as Schedule I (each a
“Purchaser” and, collectively, the “Purchasers”), as such Schedule I may be amended in accordance with Section 12 hereof.     

RECITALS 
 A. On the terms
and subject to the conditions set forth herein, each Purchaser, severally and not jointly, is willing to purchase from the Company, and the Company is willing to sell to such Purchaser, an unsecured subordinated convertible Note (as defined below)
in the principal amount set forth opposite such Purchaser’s name on Schedule I hereto. 
 B. Capitalized terms not otherwise
defined herein shall have the meaning set forth in the form of Note (as defined below) attached hereto as Exhibit A.  

AGREEMENT 
 NOW THEREFORE,
in consideration of the foregoing, and the representations, warranties, and conditions set forth below, the parties hereto, intending to be legally bound, hereby agree as follows: 

1. The Purchase and Sale of the Notes. 

(a) Issuance of Notes. Subject to all of the terms and conditions hereof, the Company agrees to issue and sell to each of the
Purchasers, and each of the Purchasers severally and not jointly agrees to purchase, one or more promissory notes in the form of Exhibit A hereto (each, a “Note” and, collectively, the “Notes”)
in the principal amount set forth opposite the respective Purchaser’s name on Schedule I. The obligations of the Purchasers to purchase Notes are several and not joint. The aggregate principal amount for all Notes issued hereunder shall
not exceed $35,000,000.00.  
 (b) Interest; Original Issue Discount.

 The Notes shall not bear interest; provided that upon the occurrence and during the
continuance of any Event of Default, all outstanding Obligations shall bear interest during such period at an interest rate per annum equal to the Default Rate to the fullest extent permitted by applicable laws of the State of New York and shall be
payable on demand. All interest under the Notes shall be computed on the basis of a year of 365 days (or 366 days in a leap year), and in each case shall be payable for the actual number of days elapsed (including the first day but excluding the
last day). The Company and each Purchaser agree that each Note will be issued to the respective Purchaser for an amount equal to the product of the face amount of each Note (the “Original Note Amount”)
multiplied by 0.90 (with such original issue discount being equated to interest and being net funded from the proceeds of the issuance of the Notes). For the avoidance of doubt, (i) on the Effective Date, each Purchaser shall advance to the
Company an amount equal to the product of the Original Note Amount multiplied by 0.90 in exchange for the Company’s obligations to repay in full the Original Note Amount in accordance with the terms hereof and (ii) all calculations of
amounts payable in respect of the Notes will be calculated on the basis of each Note’s full stated principal amount. The original issue discount on each Note pursuant to this Section 1(b) shall be deemed earned in full by each
Purchaser on and as of the Effective Date. 
 The original issue discount hereunder shall in no event exceed the maximum rate permissible
under applicable law. If such original issue discount hereunder is ever reduced as a result of this paragraph and at any time thereafter the maximum rate permitted by the laws of the State of New York shall exceed the rate of equated interest
provided for in each Note, then such equated rate provided for in each Note shall be increased to the maximum rate provided by the laws of the State of New York for such period as is required so that the total amount of equated interest received by
each Purchaser is that which would have been received by each Purchaser but for the operation of the first sentence of this paragraph. 
 (c)
Closing. The sale and purchase of one or more of the Notes shall take place remotely via exchange of signatures on the date hereof (the “Effective Date”). On the Effective Date, the Company will deliver
to each of the Purchasers participating on the Effective Date the Note to be purchased by such Purchaser, against receipt by the Company of the corresponding purchase price set forth on Schedule I (the “Purchase
Price”), taking into account Section 1(b). The Purchase Price may be paid in cash payable to the Company or, in lieu of cash, in the form of exchange of the principal value of Unsecured Subordinated Promissory Notes issued
by the Company and held by such Purchaser. 
 2. Maturity Date; Payments and Prepayments.

(a) The principal of and other amounts payable under each Note shall be immediately due and payable in full in cash on the earliest of:
(i) December 31, 2022 (the “Maturity Date”); (ii) the acceleration of the obligations under any Note as provided in Section 10 upon the occurrence and during the continuance of an Event of
Default; or (iii) the sale of all or substantially all of the assets of the Company. 
 (b) Prepayment, in whole or in part, is only
permitted with consent of the Majority in Interest Purchasers and in compliance with Section 3 herein. Any such prepayment or any other payment on the Notes will be without premium or penalty and shall include any accrued interest on the
principal amount prepaid and any other amounts then due and payable hereunder or under the Notes, and be applied to the payment of the aggregate principal amount of the Notes on a pro rata basis among all of the Notes. The Company may not reborrow
any amounts repaid or prepaid under any Note. 
 (c) All payment and prepayments shall be denominated in U.S. dollars. 

 The Company hereby agrees that its obligation to make payments when due hereunder is
absolute and unconditional and shall not be subject to refund, return, offset, deduction, cross-collateralization or counterclaim of any kind for any reason, and the Company hereby waives all defenses to payment thereof on the date such payments are
due pursuant to the terms hereof. 
 3. Subordination. Notwithstanding anything to the contrary herein, the payment of the
Obligations evidenced by the Notes, and the exercise of the rights of the Purchasers hereunder are each expressly subject and subordinated to the prior payment in full of the obligations under the Senior Notes purchased under the Senior Note
Purchase Agreement, in accordance with the Subordination Agreement. The Obligations evidenced by the Notes shall be senior in right of payment to all existing and future subordinated and unsecured indebtedness of the Company. 

4. Representations, Warranties and Covenants of the Company. The Company represents, warrants and covenants to each Purchaser
that: 
 (a) Due Incorporation, Qualification, etc. The Company (i) is a public limited company (naamloze
vennootschap) duly incorporated, validly existing and in good standing under Dutch law; and (ii) has the power and authority to own, lease and operate its properties and carry on its business as now conducted in all material respects. 

(b) Authority. The execution, delivery and performance by the Company of this Agreement and the Notes (collectively, the
“Note Documents”) to be executed by the Company and the consummation of the transactions contemplated hereby and thereby (i) are within the power of the Company and (ii) have been duly authorized by
all necessary actions on the part of the Company. 
 (c) Enforceability. Each Note Document executed, or to be executed, by the
Company has been, or will be, duly executed and delivered by the Company and constitutes, or will constitute, a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as limited by
bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors’ rights generally and general principles of equity. 

(d) Non-Contravention. The execution and delivery by the Company of the Note Documents executed
by the Company and the performance and consummation of the transactions contemplated hereby and thereby do not and will not violate any provision of, or result in the breach or the acceleration of, or entitle any other person to accelerate (whether
after the giving of notice or lapse of time or both), any material mortgage, indenture, agreement, instrument or contract to which the Company is a party or by which it is bound. 

(e) Approvals. No material consent, approval, order or authorization of, or registration, declaration or filing with, any governmental
authority or other person (including, without limitation, the shareholders of any person) is required in connection with the execution and delivery of the Note Documents executed by the Company and the performance and consummation of the
transactions contemplated hereby and thereby, other than such as have been obtained and remain in full force and effect and other than such qualifications or filings under applicable securities laws as may be required in connection with the
transactions contemplated by this Agreement.  
 (f) Use of Proceeds. The proceeds of the Notes shall be used (1) to pay
fees and expenses in connection with the transactions contemplated hereby and (2) for working capital and general corporate purposes of the Company.  

(g) Notice of Event of Default. As soon as possible, and in any event within five (5) Business Days after the Company becoming
aware of the occurrence of an Event of Default, an authorized officer of the Company shall deliver to the Purchasers a written statement setting forth the details of such Event of Default.  

 5. Representations and Warranties of Purchasers. Each Purchaser, for that
Purchaser alone, represents and warrants to the Company upon the acquisition of a Note that such Purchaser has full legal capacity, power and authority to execute and deliver this Agreement and to perform its obligations hereunder. The Note
Documents constitute valid and binding obligations of such Purchaser, enforceable in accordance with their terms, except as limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of
creditors’ rights generally and general principles of equity. 
 6. Mandatory Conversion of Notes. Pursuant
to an Event of Conversion outlined in this Section 6, in the event of an Equity Financing, Qualified Listing Transaction or Change of Control Transaction (each an “Event of Conversion”) detailed below, the Notes
shall automatically and irrevocably be converted into ordinary shares of the Company. Upon conversion of the notes and issuance of the Conversion Shares, the Purchasers agree to, or cause one of its Affiliates that is Purchaser’s designee to
receive the Conversion Shares to, comply with and be bound by the terms, conditions and provisions of the Company’s Articles of Association and the Amended and Restated Shareholders’ Agreement regarding Agendia N.V. and the Relationship
Agreement, as it may be amended and/or restated, then in effect and to execute and become party to all customary agreements that the Company reasonably requests in connection with such share issuance. 

(a) Equity Financing. Upon the closing of an Equity Financing, the Original Note Amount of each Purchaser shall automatically be
converted into Conversion Shares without any action on the part of the Company or each Purchaser. The number of Conversion Shares to be issued upon such conversion shall be equal to the quotient obtained by dividing the Original Note Amount by the
Equity Financing Conversion Price. The Company shall notify each Purchaser in writing of the anticipated occurrence of an Equity Financing at least five days prior to the closing date of the Equity Financing, notifying each Purchaser of the
conversion to be effected and the terms under which the equity securities of the Company are anticipated to be sold in such Equity Financing. The issuance of Conversion Shares pursuant to the conversion of each Note shall be upon and subject to the
same terms and conditions applicable to the equity securities of the Company sold in the Equity Financing. 
 (b) Qualified Listing
Transaction. Upon the closing of a Qualified Listing Transaction, the Original Note Amount of each Purchaser shall automatically be converted into Conversion Shares without any action on the part of the Company or each Purchaser. The number of
Conversion Shares to be issued upon such conversion shall be equal to the quotient obtained by dividing the Original Note Amount by the Qualified Listing Transaction Conversion Price. The Company shall notify each Purchaser in writing of the
anticipated occurrence of a Qualified Listing Transaction at least five days prior to the closing date of the Qualified Listing Transaction, notifying each Purchaser of the conversion to be effected and the terms under which the equity securities of
the Company are anticipated to be sold in such Qualified Listing Transaction. The issuance of Conversion Shares pursuant to the conversion of each Note shall be upon and subject to the same terms and conditions applicable to the equity securities of
the Company sold in the Qualified Listing Transaction. 
 (c) Change of Control Transaction. Other than a Qualified Listing
Transaction or Equity Financing, if there is a Change of Control of the Company in which all or substantially all of the shares of the Company are acquired in a single transaction or series of transactions pursuant to definitive documents approved
by the shareholders of the Company, immediately prior to first closing of such transaction, the Original Note Amount of each Purchaser shall automatically be converted into Conversion Shares without any action on the part of the Company or each
Purchaser. The number of Conversion Shares 

 
to be issued upon such conversion shall be equal to the quotient obtained by dividing the Original Note Amount by the Change of Control Conversion Price. The Company shall notify each Purchaser
in writing of the anticipated occurrence of a Change of Control at least five days prior to the closing date of the Change of Control transaction, notifying each Purchaser of the conversion to be effected and the terms under which the equity
securities of the Company are anticipated to be sold in such Change of Control. The issuance of Conversion Shares pursuant to the conversion of each Note shall be upon and subject to the same terms and conditions applicable to the equity securities
of the Company sold in the Change of Control transaction. Each Purchaser hereby agrees to execute and become party to all customary agreements that the Company reasonably requests in connection with such Change of Control transaction. 

(d) No Voluntary Conversion. No purchaser may voluntarily elect to convert its Note and each Purchaser acknowledges and agrees that each
Note shall only be converted pursuant to the automatic mandatory conversion provisions set forth in clauses (a), (b) and (c) above. 

(e) No Fractional Shares. Upon the conversion of a Note into Conversion Shares, any fraction of a share will be rounded down to the next
whole share of Conversion Shares. No payment will be made to a Purchaser in lieu of any fractional shares to which a Purchaser would otherwise have been entitled, and such amounts shall be extinguished without any further payment on the part of the
Company. 
 7. Conditions to Closing. Each Purchaser’s obligations on the Effective Date are subject to the fulfillment,
on or prior to the Effective Date, of all of the following conditions, any of which may be waived in whole or in part by such Purchaser: 

(a) Representations and Warranties. The representations and warranties made by the Company in Section 4 hereof shall be true
and correct on the Effective Date; 
 (b) Officer’s Certificate. The delivery of an officer’s certificate certifying as of
the date hereof (1) copies of the governing documents of the Company, certified by the Secretary of State of its jurisdiction of organization; (2) resolutions of the board of directors of the Company approving and authorizing the
execution, delivery and performance of this Agreement and the other Note Documents; and (3) signature and incumbency certificates of the officers of the Company executing the Note Documents; 

(c) Execution of Note Documents. The execution and delivery of each Note Document, in each case, by the Company and the respective
Purchaser; 
 (d) Minimum Issuance. The issuance by the Company and the purchase by one or more Purchasers of Notes hereunder in an
aggregate principal amount of not less than $30,000,000; and 
 (e) Amendment to Senior Note Purchase Agreement. The execution and
delivery of an amendment to the Senior Note Purchase Agreement that amends the Senior Note Purchase Agreement to, among other things, permit the incurrence by the Company of the Obligations under the Notes. 

8. Conditions to Obligations of the Company. The Company’s obligation to issue and sell the Notes on the Effective Date is
subject to the fulfillment, on or prior to the Effective Date of the following conditions, any of which may be waived in whole or in part by the Company: 

(a) Representations and Warranties. The representations and warranties made by the Purchasers in Section 5 hereof shall be
true and correct on the Effective Date. 
 (b) Purchase Price. Each Purchaser shall have delivered to the Company the Purchase Price
in respect of the Note purchased by such Purchaser referenced in Section 1(c). 

 9. Events of Default. The occurrence of any of the following constitutes an
“Event of Default”: 
 (a) The Company shall fail to pay (1) when due any principal
under any Note or (2) any interest on any Note or any other amount payable under any Note within three (3) days following the due date thereof; or 

(b) The Company defaults in the performance of or compliance with any term contained in this Agreement or any Note and such default is not
remedied or waived within ten (10) days after the earlier of (1) receipt by the Company of notice from a Purchaser of such default or (2) actual knowledge of an officer of the Company of such default; or 

(c) An Event of Default (as defined in the Senior Note Purchase Agreement) occurs and is continuing in respect of the Senior Note Purchase
Agreement and the notes purchased thereunder (the “Senior Notes”) and the holders of the Senior Notes accelerate the obligations under such Senior Notes, provided, however, that an Event of Default under this
Section 9(c) shall be deemed cured, rescinded and of no force or effect if the acceleration of the Senior Notes has been cured or rescinded; or 

(d) The Company, or any of its material subsidiaries, shall commence a voluntary case or other proceeding seeking liquidation, reorganization
or other relief with respect to itself or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of it or any
substantial part of its property, or shall consent to any such relief or to the appointment of or taking possession by any such official in an involuntary case or other proceeding commenced against it, or shall make a general assignment for the
benefit of creditors, or formally admits in writing its inability or shall fail generally to pay its debts as they become due, or shall take any corporate action to authorize any of the foregoing; or 

(e) An involuntary case or other proceeding shall be commenced against the Company, or any of its material subsidiaries, seeking liquidation,
reorganization or other relief with respect to it or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of it
or any substantial part of its property, and such involuntary case or other proceeding shall remain undismissed, unbonded or unstayed for a period of sixty (60) days; or a final order for relief by a court of competent jurisdiction shall be
entered against the Company, or any of its material subsidiaries, under the federal bankruptcy laws as now or hereafter in effect; or 
 (f)
A Change of Control occurs, unless the Notes are paid in full or converted pursuant to Section 6 hereof, in connection with the closing of such transaction or each Purchaser has provided its prior written consent to such Change of Control;
provided that any Change of Control is subject to the automatic mandatory conversion provisions of Section 6 hereof; or 

(g) Any representation, warranty, certification or statement of fact made or deemed made by or on behalf of the Company herein, in any other
Note Document, or in any document delivered in connection herewith or therewith shall be incorrect or misleading in any material respect (and in all respects if any such representation or warranty is already qualified by materiality or reference to
Material Adverse Effect) when made or deemed made; or 
 (h) (1) There is entered against the Company one or more final judgments or
orders for the payment of money in an aggregate amount exceeding the Threshold Amount (as defined in the Senior Note Purchase Agreement) to the extent not covered by independent third-party insurance as to which the insurer does not dispute coverage
or (2) any one or more non-monetary final judgments that have, or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect and, in either case,
(A) enforcement proceedings are commenced by any creditor upon such judgment or order or (B) there is a period of thirty (30) consecutive dates during which a stay of enforcement, by reason of a pending appeal or otherwise, is not in
effect; or 

 (i) Any Note Document, at any time after its execution and delivery and for any reason other
than as expressly permitted hereunder or thereunder, ceases to be in full force and effect; or the Company contests in any manner the validity or enforceability of any Note Document; or the Company denies that it has any or further liability or
obligation under any Note Document, or purports to revoke, terminate or rescind any Note Document. 
 10. Rights and Remedies Upon
Default. Upon the occurrence of any Event of Default (other than an Event of Default described in Sections 9(d) or 9(e)) and at any time thereafter during the continuance of such Event of Default, the Majority in Interest
Purchasers may declare all outstanding Obligations to be immediately due and payable without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived, anything contained herein to the contrary
notwithstanding. Upon the occurrence of any Event of Default described in Sections 9(d) or 9(e), immediately and without notice, all outstanding Obligations automatically become immediately due and payable, without presentment, demand,
protest or any other notice of any kind, all of which are hereby expressly waived, anything contained herein to the contrary notwithstanding. In addition to the foregoing remedies, upon the occurrence and during the continuance of any Event of
Default, the Majority in Interest Purchasers may exercise any other right power or remedy granted to it hereby, or otherwise permitted to it by law, either by suit in equity or by action at law, or both. 

11. Definitions. As used in the Note Documents, the following capitalized terms have the following meanings: 

“Affiliate” has the meaning set forth in the Senior Note Purchase Agreement. 

“Business Day” means any day except a Saturday, Sunday or other day on which either the New York Stock Exchange is
closed, or on which commercial banks in New York, New York are authorized by law to close. 
 “Change of Control”
has the meaning set forth in the Senior Note Purchase Agreement. 
 “Change of Control Conversion Price” shall mean
0.95 multiplied by either, as applicable, (a) for cash transactions, the initial cash distribution to each ordinary share of the Company in connection with such Change of Control transaction or (b) for equity securities or equity
securities and cash transactions, the initial aggregate consideration distributed to each ordinary share, including cash plus the fair value of equity securities to be received. For purposes of clause (b), in the case of (x) equity
securities traded on an internationally recognized exchange, the fair value of the equity securities will equal the simple average of the closing prices, as reported at the close of regular trading by the principal exchange of such equity
securities, for the four (4) business days preceding the day which is two (2) business days before closing of such transaction or (y) equity securities not traded on an internationally recognized exchange, the fair value of the equity
securities will equal an amount determined in good faith by the board of the Company. 
 “Conversion Shares” means
the equity securities of the Company issued in connection with the Equity Financing, Qualified Listing Transaction or Change of Control, as applicable. 

“Default Rate” means an interest rate equal to two percent (2.00%) per annum, to the fullest extent permitted by
applicable laws of the State of New York. 

 “Equity Financing” means an equity financing of the Company
with one or more investors that results in gross proceeds to the Company of at least $10,000,000 in the aggregate from such investors, other than a Qualified Listing Transaction. 

“Equity Financing Conversion Price” shall mean 0.85 multiplied by the price paid per share for equity securities of
the Company by the other investors in the Equity Financing. 
 “Event of Default” has the meaning given in
Section 9 hereof. 
 “Material Adverse Effect” has the meaning set forth in the Senior Note
Purchase Agreement. 
 “Obligations” shall mean and include all loans, advances, debts, liabilities and obligations,
howsoever arising, owed by the Company to the Purchasers of every kind and description, now existing or hereafter arising under or pursuant to the terms of the Note Documents, including, all interest, fees, charges, expenses, reasonable and
documented attorneys’ fees and costs and accountants’ fees and costs chargeable to and payable by the Company hereunder and thereunder, in each case, whether direct or indirect, absolute or contingent, due or to become due, and whether or
not arising after the commencement of a proceeding under Title 11 of the United States Code (11 U. S. C. Section 101 et seq.), as amended from time to time (including post-petition interest) and whether or not allowed or allowable as a
claim in any such proceeding. 
 “Person” shall mean and include an individual, a partnership, a corporation (including a
business trust), a joint stock company, a limited liability company, an unincorporated association, a joint venture or other entity or a governmental authority. 

“Qualified Listing Transaction” shall mean either (i) an Initial Public Offering, (ii) a Direct Listing or
(iii) a SPAC Combination, in each case, which results in aggregate gross proceeds of at least $40,000,000 in the aggregate. 

“Qualified Listing Transaction Conversion Price” shall mean 1.0 multiplied by, as applicable, (a) the offering
price of shares of equity securities of the Company in connection with an underwritten public offering under the Securities Act of 1933, as amended, (an “Initial Public Offering”); (b) the average of the daily volume
weighted average price for equity securities of the Company over the five (5) trading day period following a direct listing transaction (a “Direct Listing”); or (c) in the case of a business combination of the
Company and a SPAC, the lower of (1) the offering price for shares of common stock of the SPAC in its Initial Public Offering and (2) the offering price for shares of common stock offered to investors in connection with the business
combination of the SPAC and the Company (in each case, referred to as a “SPAC Combination”). 

“Senior Note Purchase Agreement” shall mean that certain Note Purchase Agreement, dated as of July 24, 2018,
among the Company, the purchasers from time to time party thereto and Athyrium Opportunities III Acquisition LP, a Delaware limited partnership, as collateral agent for the purchasers from time to time party thereto (as amended, restated,
supplemented, refinanced, replaced, extended or otherwise modified from time to time). 
 “Senior Notes” has the
meaning given in Section 9(c) hereof. 
 “SPAC” means a special purpose acquisition entity, which
(i) has been formed with the purpose of raising capital, (ii) has completed an initial public offering resulting in the equity interests of such entity being listed on a United States national securities exchange, and (iii) does not
conduct any material business or maintain any material assets other than cash. 
 “Subordination Agreement” shall
mean that certain Subordination Agreement, dated as of the date hereof, between the Company, Athyrium Opportunities III Acquisition LP and the Purchasers (as amended, restated, supplemented or otherwise modified from time to time). 

 12. Miscellaneous. 

(a) Waivers and Amendments. Any provision of this Agreement and the Notes may be amended, waived or modified only upon the written
consent of the Company and Purchasers holding at least a majority of the aggregate outstanding principal amount of the Notes (the “Majority in Interest Purchasers”); provided, however, that no such
amendment, waiver or consent shall: (i) reduce or forgive the principal amount of any Note or any other amount due under this Agreement or any Note, (ii) reduce the rate of interest of any Note, (iii) extend the Maturity Date or any
other date on which any amount under any Note Document is due and payable or (iv) fail to apply equally to all Purchasers of the Notes, in each case, without the written consent of each Purchaser directly affected thereby. Any amendment or
waiver effected in accordance with this paragraph shall be binding upon all of the parties hereto. 
 (b) Governing Law. THIS
AGREEMENT AND EACH OTHER NOTE DOCUMENT SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES THAT WOULD APPLY A DIFFERENT LAW. EACH PARTY
HERETO HEREBY CONSENTS TO THE EXCLUSIVE JURISDICTION OF ANY STATE OR FEDERAL COURT LOCATED WITHIN THE COUNTY OF NEW YORK, STATE OF NEW YORK AND IRREVOCABLY AGREES THAT ALL ACTIONS OR PROCEEDINGS ARISING OUT OF OR RELATING TO THE NOTE DOCUMENTS SHALL
BE LITIGATED IN SUCH COURTS. EACH PARTY HERETO EXPRESSLY SUBMITS AND CONSENTS TO THE JURISDICTION OF THE AFORESAID COURTS AND WAIVES ANY DEFENSE OF FORUM NON CONVENIENS. EACH PARTY HERETO HEREBY WAIVES PERSONAL SERVICE OF ANY AND ALL PROCESS AND
AGREES THAT ALL SUCH SERVICE OF PROCESS MAY BE MADE UPON SUCH PARTY BY CERTIFIED OR REGISTERED MAIL, RETURN RECEIPT REQUESTED, ADDRESSED TO SUCH PARTY AT THE ADDRESS SET FORTH IN THIS AGREEMENT AND SERVICE SO MADE SHALL BE COMPLETE TEN
(10) DAYS AFTER THE SAME HAS BEEN POSTED. 
 (c) Waiver of Jury Trial. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL
RIGHT TO TRIAL BY JURY IN ANY LEGAL ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THE NOTE DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY AND AGREES THAT ANY SUCH ACTION OR PROCEEDING SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A JURY. EACH
PARTY HERETO ACKNOWLEDGES THAT THIS WAIVER IS A MATERIAL INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP, THAT EACH HAS RELIED ON THE WAIVER IN ENTERING INTO THE NOTE DOCUMENTS, AND THAT EACH WILL CONTINUE TO RELY ON THIS WAIVER IN THEIR RELATED
FUTURE DEALINGS. EACH PARTY HERETO WARRANTS AND REPRESENTS THAT EACH HAS HAD THE OPPORTUNITY OF REVIEWING THIS JURY WAIVER WITH LEGAL COUNSEL, AND THAT EACH KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS. 

(d) Survival. The representations, warranties, covenants and agreements made herein shall survive the execution and delivery of this
Agreement. 
 (e) Successors and Assigns. Subject to the restrictions on transfer described in this Section 12(e), the
rights and obligations of the Company and the Purchasers shall be binding upon and benefit their successors, assigns, heirs, administrators and transferees. Neither this Agreement, the Notes, nor any of the rights, interests or obligations hereunder
and thereunder may be assigned, by operation of law or otherwise, in whole or in part, by the Company without the prior written consent of each Purchaser. Any Purchaser may transfer, without restriction, Notes to one or more of its Affiliates with
the prior written consent of the Company, which will not be unreasonably withheld; provided that upon the occurrence and during the continuance of an Event of Default, no such consent of the Company shall be required. 

 (f) Partial Invalidity; Entire Agreement. If at any time any provision of this
Agreement or any Note is or becomes illegal, invalid or unenforceable in any respect under the law or any jurisdiction, neither the legality, validity or enforceability of the remaining provisions of this Agreement or any Note nor the legality,
validity or enforceability of such provision under the law of any other jurisdiction shall in any way be affected or impaired thereby. This Agreement and the Notes constitute and contain the entire agreement among the Company and Purchasers and
supersede any and all prior agreements, negotiations, correspondence, understandings and communications among the parties, whether written or oral, respecting the subject matter hereof. 

(g) Notices. All notices, requests, demands, consents, instructions or other communications required or permitted hereunder shall be in
writing and faxed, mailed, electronically mailed or delivered (including by an international courier service of recognized standing) to each party at such address, e-mail address or facsimile number as set
forth on the signature pages hereto or such other address, e-mail address or facsimile number as shall have been furnished to by each party to the other in writing. All such notices and communications will be
deemed effectively given the earlier of (i) when received, (ii) when delivered personally, (iii) one Business Day after being delivered by facsimile (with receipt of appropriate confirmation), (iv) one Business Day after being
deposited with an overnight courier service of recognized standing, (v) if sent to an e-mail address, upon the sender’s receipt of an acknowledgement from the intended recipient (such as by the
“return receipt requested” function, as available, return e-mail or other written acknowledgement) or (vi) four days after being deposited in the U.S. mail, first class with postage prepaid.

 (h) Separability of Agreements; Severability of this Agreement. The Company’s agreement with each of the Purchasers is a
separate agreement and the sale of the Notes to each of the Purchasers is a separate sale. Unless otherwise expressly provided in the Note Documents, the rights of each Purchaser hereunder are several rights, not rights jointly held with any of the
other Purchasers. Any invalidity, illegality or limitation on the enforceability of the Agreement or any part thereof, by any Purchaser whether arising by reason of the law of the respective Purchaser’s domicile or otherwise, shall in no way
affect or impair the validity, legality or enforceability of this Agreement with respect to other Purchasers. If any provision of this Agreement shall be judicially determined to be invalid, illegal or unenforceable, the validity, legality and
enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 
 (i) Waivers. The Company hereby
waives notice of default, presentment or demand for payment, protest or notice of nonpayment or dishonor and all other notices or demands relative to this instrument. No failure or delay on each Purchaser’s part in exercising any right
hereunder shall operate as a waiver thereof or of any other right nor shall any single or partial exercise of any such right preclude any other further exercise thereof or of any other right. 

(j) Indemnification. In addition to the Company’s other Obligations under this Agreement, the Company agrees to defend, protect,
indemnify and hold harmless each Purchaser and all of their respective officers, directors, employees, attorneys, consultants and agents (collectively called the “Indemnitees”) from and against any and all losses, damages,
liabilities, obligations, penalties, documented out-of-pocket fees, costs and expenses (including, without limitation, reasonable attorneys’ fees, costs and
expenses) incurred by such Indemnitees as a result of or arising from or relating to or in connection with the negotiation, preparation, execution or performance or enforcement of this Agreement, any other Note Document or of any other document
executed in connection with the transactions contemplated by this Agreement or any claim, litigation, investigation or proceeding relating to any of the foregoing, whether or 

 
not any Indemnitee is a party thereto (collectively, the “Indemnified Matters”); provided, however, that the Company shall not have any obligation to any
Indemnitee under this subsection (j) for any Indemnified Matter caused by the bad faith, gross negligence or willful misconduct of such Indemnitee, as determined by a final non- appealable judgment of a
court of competent jurisdiction. This subsection (j) shall not apply with respect to taxes other than any taxes that represent losses, damages, liabilities, etc. arising from any non-tax claim. This
subsection (j) shall survive repayment in full of the Notes and termination of the Notes. 
 (k) Counterparts. This Agreement may
be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall be deemed to constitute one instrument. Delivery of an executed counterpart of a signature page of this Agreement by facsimile or
other electronic transmission is as effective as delivery of a manually executed counterpart of this Agreement. 
 (signature page
follows) 

 This Convertible Note Purchase Agreement has been executed by the undersigned as of the date
stated in the introductory clause. 
  

			
	AGENDIA N.V.,
	a public limited company (naamloze vennootschap) incorporated under Dutch law
		
	By:	 	 /s/ Mark R. Straley

	Name: Mark R. Straley
	Title: Chief Executive Officer
		
	By:	 	 /s/ Brian B. Dow

	Name: Brian B. Dow
	Title: Chief Financial Officer

 [Signature Page to Note Purchase Agreement] 

 This Note Purchase Agreement has been executed by the undersigned as of the date stated in
the introductory clause. 
  

			
	PURCHASER:
	
	NORGINE VENTURES B.V.
		
	By:	 	 /s/ Peter Stein

	Name:	 	Peter Stein
	Title:	 	Director

 [Signature Page to Note Purchase Agreement] 

 This Note Purchase Agreement has been executed by the undersigned as of the date stated in
the introductory clause. 
  

			
	PURCHASER:
	
	 ATHYRIUM OPPORTUNITIES III

ACQUISITION LP, a Delaware limited partnership

	
	 By: ATHYRIUM OPPORTUNITIES

ASSOCIATES III LP, its general partner

	
	 By: ATHYRIUM OPPORTUNITIES

ASSOCIATES III GP LLC, its general partner

		
	By:	 	 /s/ Rashida Adams

	Name: Rashida Adams
	Title: Authorized Signatory

 [Signature Page to Note Purchase Agreement] 

 This Note Purchase Agreement has been executed by the undersigned as of the date stated in
the introductory clause. 
  

									
	PURCHASER:	 		 		 	
		
	KORYS INVESTMENTS NV	 	
				
	By:	 	 /s/ Piet Colruyt
	 		 	 /s/ Vincent Vliebergh

	Name:	 	Piet Colruyt	 		 	Mazerine Partners SPRL, repr. by Vincent Vliebergh,
	Title:	 	Director	 		 	Director	 	

 [Signature Page to Note Purchase Agreement] 

 This Note Purchase Agreement has been executed by the undersigned as of the date stated in
the introductory clause. 
  

			
	HARTWIG HOUDSTERMAATSCHAPPIJ B.V.
		
	By:	 	 /s/ R.H. Defares

	Name: R.H. Defares
	Title: Director

 [Signature Page to Note Purchase Agreement] 

 This Note Purchase Agreement has been executed by the undersigned as of the date stated in
the introductory clause. 
  

									
	PURCHASER:	 		 		 	
		
	STICHTING LICHFIELD	 	
				
	By:	 	 /s/ J.H. Wolkers
	 		 	 /s/ G.H.M. Vehmeijer

	Name:	 	J.H. Wolkers	 		 	G.H.M. Vehmeijer
	Title:	 		 		 		 	

 [Signature Page to Note Purchase Agreement] 

 This Note Purchase Agreement has been executed by the undersigned as of the date stated in
the introductory clause. 
  

			
	PURCHASER:
	
	P.H.C.J. VAN DOORNE
		
	By:	 	 /s/ P.H.C.J. Van Doorne

	Name: P.H.C.J. Van Doorne
	Title:

  

  
 [Signature Page to Note
Purchase Agreement] 

 This Note Purchase Agreement has been executed by the undersigned as of the date stated in
the introductory clause. 
  

			
	PURCHASER:
	
	B.H.R. HILTERMANN BEHEER BV
		
	By:	 	 /s/ B.H.R Hiltermann

	Name: B.H.R Hiltermann
	Title: CEO

  

  
 [Signature Page to Note
Purchase Agreement] 

 This Note Purchase Agreement has been executed by the undersigned as of the date stated in
the introductory clause. 
  

			
	PURCHASER:
	
	G&M LINNAEUSPARK B.V.
		
	By:	 	 /s/ Gert jan van der Baan Beheer BV

	Name:	 	Gert jan van der Baan
	Title:	 	Managing Director

  

  
 [Signature Page to Note
Purchase Agreement] 

 This Note Purchase Agreement has been executed by the undersigned as of the date stated in
the introductory clause. 
  

			
	PURCHASER:
	
	H. BRULLEMAN
		
	By:	 	 /s/ Henk Brulleman

	Name: Henk Brulleman
	Title: Natural person - not applicable

  

  
 [Signature Page to Note
Purchase Agreement] 

 This Note Purchase Agreement has been executed by the undersigned as of the date stated in
the introductory clause. 
  

			
	PURCHASER:
	
	B.S. VAN DER BAAN
		
	By:	 	 /s/ Bastiaan van der Baan

	Name: Bastiaan van der Baan
	Title:   Chief Clinical Affairs & Business Dev Officer
	           Agendia

  

  
 [Signature Page to Note
Purchase Agreement] 

 This Note Purchase Agreement has been executed by the undersigned as of the date stated in
the introductory clause. 
  

			
	PURCHASER:
	
	MARK R. STRALEY
		
	By:	 	 /s/ Mark R. Straley

  

  
 [Signature Page to Note
Purchase Agreement] 

 This Note Purchase Agreement has been executed by the undersigned as of the date stated in
the introductory clause. 
  

			
	PURCHASER:
	
	BRIAN B. DOW
		
	By:	 	 /s/ Brian B. Dow

  

  
 [Signature Page to Note
Purchase Agreement] 

 This Note Purchase Agreement has been executed by the undersigned as of the date stated in
the introductory clause. 
  

			
	
	PURCHASER:
	
	SIRSHENDU ROOPOM BANERJEE
		
	By:	 	 /s/ Sirshendu Roopom Banerjee

  

  
 [Signature Page to Note
Purchase Agreement] 

 SCHEDULE I 

SCHEDULE OF PURCHASERS 
  

  
 1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}]]